<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/sutro-biopharma-inc-logo-1200x675.png/query-dj0yMDI0MDUyOTEyMzMyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/sutro-biopharma-inc-logo-1200x675.png/query-dj0yMDI0MDUyOTEyMzMyMg"/>Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) insider David Pauling acquired 12,504 shares of Sutro Biopharma stock in a transaction on Wednesday, October 15th. The shares were purchased at an average price of $0.80 per share, with a total value of $10,003.20. Following the completion of the purchase, the insider owned 71,737 shares in the company, valued at $57,389.60. This represents a 21.11% increase in their position. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website.</p><h2>Sutro Biopharma Stock Performance</h2><p>Shares of NASDAQ STRO opened at $0.88 on Friday. The firm's 50 day moving average price is $0.88 and its 200-day moving average price is $0.83. Sutro Biopharma, Inc. has a 52-week low of $0.52 and a 52-week high of $4.60. The company has a market cap of $74.66 million, a PE ratio of -0.35 and a beta of 1.61. </p><p>Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.25. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $14.55 million.  On average, analysts forecast that  Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year. </p><h2>Analyst Ratings Changes</h2><hr/><hr/><p>A number of equities research analysts have recently commented on the stock. Wells Fargo &amp; Company cut their price target on shares of Sutro Biopharma from $4.00 to $3.00 and set an &#34;equal weight&#34; rating on the stock in a report on Tuesday, August 12th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Sutro Biopharma in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Sutro Biopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, September 13th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued  a Sell rating to the stock. According to data from MarketBeat, Sutro Biopharma  has an average rating of &#34;Hold&#34; and an average target price of $4.47.</p><p><b>Read Our Latest Stock Report on STRO</b></p><h2>Institutional Trading of Sutro Biopharma</h2><p>Institutional investors have recently made changes to their positions in the stock. Catalyst Funds Management Pty Ltd purchased a new stake in shares of  Sutro Biopharma during the 2nd quarter valued at about $27,000.  Cerity Partners LLC purchased a new stake in shares of  Sutro Biopharma during the 1st quarter valued at about $25,000.  Vontobel Holding Ltd. boosted its holdings in shares of  Sutro Biopharma by 100.0% during the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after acquiring an additional 25,000 shares during the last quarter.  Savant Capital LLC purchased a new stake in shares of  Sutro Biopharma during the 2nd quarter valued at about $37,000.  Finally, CWM LLC boosted its holdings in shares of  Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company's stock valued at $40,000 after acquiring an additional 23,941 shares during the last quarter. Hedge funds and other institutional investors own  96.99% of the company's stock. </p><h2>Sutro Biopharma Company Profile</h2><p> (Get Free Report)</p><p>Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Sutro Biopharma</li><li>How Technical Indicators Can Help You Find Oversold Stocks </li><li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li><li>Trading Halts Explained</li><li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li><li>What is Short Interest? How to Use It</li><li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Sutro Biopharma?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Sutro Biopharma and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2046push_Webinar-7.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2046push_Webinar-7.jpg"/></p><div><p>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</p><p>Right now, we’re witnessing a monumental shift in the world.</p><p><span>Traders Agency</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTM1MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTM1MQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/Screenshot%202025-07-30%20at%201.42.22%E2%80%AFPM.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="797" height="420" original-src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/Screenshot%202025-07-30%20at%201.42.22%E2%80%AFPM.png"/></p><div><p>Capital Gains Tax Strategies for Seniors</p><p>Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...</p><p><span>SmartAsset</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTE3OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTE3OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/06-Jun/BNF_AI_Metal_Spad+1%2C+4%2C+5+%2C+6.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="624" height="372" original-src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/06-Jun/BNF_AI_Metal_Spad+1%2C+4%2C+5+%2C+6.png"/></p><div><p>$100 Trillion “AI Metal” Found in American Ghost Town</p><p>Jeff Brown recently traveled to a ghost town in the middle of an American desert…  To investigate what could...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTE5NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTE5NQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2072push_NOC_MB_Display.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2072push_NOC_MB_Display.png"/></p><div><p>Bitcoin grabs headlines, but smart money likes this token</p><p>Bitcoin grabs headlines, but smart money likes this token  My research team has identified the token positio...</p><p><span>Crypto 101 Media</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDEwOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNDEwOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250916143801_pushtrumpnew-4.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250916143801_pushtrumpnew-4.jpg"/></p><div><p>If You Keep Cash In A U.S. Bank Account… Read This NOW</p><p>The Treasury Department just issued a stunning warning:  U.S. banks could lose up to $6.6 trillion of custom...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTIwMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTIwMw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_Banking-9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2060push_Banking-9.jpg"/></p><div><p>Front-Run Buffett's Shocking Gold Move</p><p>A Historic Gold Announcement Is About to Rock Wall Street?  For months, sharp-eyed analysts have watched the...</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTI3Nw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTI3Nw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2057push_gold-163519_640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2057push_gold-163519_640.jpg"/></p><div><p>$15 Fund: Turn Gold Boom into Real Income</p><p>If you've been watching gold's historic run and wondering if it's too late… I've got good news.  Because the...</p><p><span>Investors Alley</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTI3Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTI3Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250904095456_pushainewer-10.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250904095456_pushainewer-10.jpg"/></p><div><p>Buy UBER immediately</p><p>BULLISH: It's time to buy this 'hidden' AI stock  An award-winning stock-rating system has turned BULLISH on...</p><p><span>Chaikin Analytics</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTQxNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTQxNQ"/></p></div></div></div>                     </div>                 </div></div>

STRO

<p>David Pauling, an insider at Sutro Biopharma (NASDAQ:STRO), purchased 12,504 shares at $0.80 each on October 15, totaling $10,003.20. This acquisition increased his holdings to 71,737 shares, valued at $57,389.60, marking a 21.11% rise in his position. The transaction was disclosed to the SEC. Sutro Biopharma's stock opened at $0.88, with a market cap of $74.66 million and a PE ratio of -0.35. Analysts have mixed ratings on the stock, with an average target price of $4.47.</p>

David Pauling Purchases 12,504 Shares of Sutro Biopharma (NASDAQ:STRO) Stock